Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — Shareholder Meeting (November 2017)
22 slides from Nova Eye Medical's shareholder meeting presentation, Nov 28, 2017
Slide 1: Presentation to Annual General Meeting
ELLEX MEDICAL LASERS LTD (ASX:ELX) Presentation to Annual General Meeting Adelaide, Australia 28 November 2017
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Ellex Medical Lasers Ltd (Ellex). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any state
Slide 3: Presentation to 2017 Annual General Meeting
Presentation to 2017 Annual General Meeting 1. Our Opportunity 2. Our Strategy 3. Our Progress, Fiscal Year 2017 4. Our Outlook, Fiscal Year 2018 3
Slide 4: Targeting a Large and Growing Market
Targeting a Large and Grow ing Market 82m people 107m people worldwide Retinal worldwide with glaucoma Glaucoma Disease with diabetic US $4.6bn US $1.9bn retinal disease Early AMD Cataract 122m people with US $5.1bn US $3.3bn 25.3m early age-related cataract operations macular degeneration performed
Slide 5: Ellex is Structured around Three Business Streams Tied to the Opportunities
Ellex is Structured around Three Business Streams Tied to the Opportunities 1. Current Stream – Ellex Core Laser and Ultrasound business delivering stable revenue and earnings 2. The Next Stream – Ellex iTrack with SLT for the emerging drug- free glaucoma therapy that is building significant momentu
Slide 6: Laser & Ultrasound
Laser & Ultrasound 6
Slide 7: Ellex Core Laser & Ultrasound
Ellex Core Laser & Ultrasound Ellex Tango Reflex™ Ellex Eye One Ellex Ultra Q Ellex Integre Pro Scan™ Ultrasound™ Reflex™ • Ellex core business of laser & ultrasound products used by ophthalmologists worldwide has achieved revenue growth CAGR of 8% over FY2013 to FY2017. This exceeds industry growth
Slide 8: iTrack MIGS
™ iTrack MIGS 8
Slide 9: Ellex iTrack: A MIGS Device that Treats Glaucoma
Ellex iTrack ™ A MIGS Device that Treats Glaucoma • The Ellex iTrack ™ is a unique, patent-protected microcatheter for treating patients with mid stage glaucoma used to clear and flush the main ocular drainage systems to restore natural biology • Perfect compliment to Ellex SLT • Can be repeated and
Slide 10: 2RT for Early AMD
® 2RT for Early AMD 10
Slide 11: Ellex 2RT - Potentially Game-changing Interventional Treatment for Early to Intermediate AMD
Ellex 2RT ® - Potentially Game- changing Interventional Treatment for Early to Intermediate AMD • Substantial growth opportunity pending results of clinical trial. • Unique, patent-protected nano pulse laser that rejuvenates aging retinal cells, thus delaying progression to late stage AMD. • Sales t
Slide 12: Ellex Core Laser & Ultrasound Progress in FY17
Ellex Core Laser & Ultrasound Progress in FY17 • The core laser and ultrasound business provides products used everyday by ophthalmologists globally • World-leading positions in cataracts and glaucoma lasers • CAGR for revenue FY13 to FY17 is 8% • Ellex has a dominant position in SLT lasers 30% 35%
Slide 13: Core Laser & Ultrasound: Progress in FY17 (cont'd)
Ellex Core Laser & Ultrasound: Progress in FY17 (cont’d) • Core laser and ultrasound profitability relatively stable • Average fully- burdened gross margin percentage greater than 50% 13
Slide 14: Core Laser & Ultrasound: Manufacturing Upgrade
Ellex Core Laser & Ultrasound: Manufacturing Upgrade 82 Gilbert Street, Adelaide, South Australia Second Avenue, Mawson Lakes, South Australia • Expanded production footprint to 7,400sqm with increased cleanrooms capacity and precision machine shop capability • Move project took place over August 20
Slide 15: iTrack Progress in FY2017 and Q1 FY2018
Ellex iTrack ™ Progress in FY2017 and Q1 FY2018 • Sales growth in FY17H2 accelerated due to expansion of USA sales team and improvement in reimbursement effective 1 January 2017 (71% growth in FY18 Q1 in USA and globally) • Good growth in markets outside the US and sales into China • Reported sales
Slide 16: iTrack Progress in FY2017 and Q1 FY2018
Ellex iTrack ™ Progress in FY2017 and Q1 FY2018 SALES BY REGION $AM FY16 FY17 FY18 Q1 Growth % Q1FY18 Reported USA 3.9 4.7 1.2 +71 Asia 0.3 1.0 0.2 >100% Rest of World 2.2 2.5 0.6 +36% 6.3 8.2 2.0 +71% 16
Slide 17: iTrack USA Sales: Five Quarters of Growth
Ellex iTrack ™ USA Sales: Five Quarters of Growth USA iTrack™ Sales by Quarter in US$'000's 1,400 80% 1,200 70% 60% % growth since Q1FY17 1,000 50% US$'000's 800 40% 600 30% 400 20% 200 10% - 0% Q1FY17 Q2FY17 Q3FY17 Q4FY17 Q1FY18 Quarter USA growth on Q1FY17 17
Slide 18: 2018 Outlook: Strategy and the Recent Capital Raise
2018 Outlook: Strategy and the Recent Capital Raise • $23.2m raised on 2 November from Australian and US institutions to access this significant opportunity • The additional funds are being used for: • Expansion of sales and marketing of Ellex iTrack™ in the USA and in strategic markets outside the
Slide 19: 2018 Outlook: Strategy and the Recent Capital Raise (cont'd)
2018 Outlook: Strategy and the Recent Capital Raise (cont’d) • As a result of the cash flow from the core laser and ultrasound business, combined with the recent capital raise, Ellex is now well capitalised to execute its growth strategy. 19
Slide 20: 2018 Outlook
2018 Outlook: • Sales within the Core Laser and Ultrasound business through to 31 October 2017 are 2% above sales for the same period in FY17 after allowing for the appreciation of the Australian dollar against the YEN, Euro and US$. • Ellex lasers for treating glaucoma and for treating vitreous opa
Slide 21: For further information on Ellex Medical Lasers please contact
For further information on Ellex Medical Lasers please contact: Tom Spurling Maria Maieli Andrew Angus CEO CFO & Company Secretary Investor Relations m: +61 417 818 658 w: +61 8 7074 8200 w: +61 402 823 757 e: tspurling@ellex.com e: mmaieli@ellex.com e: andrewangus@overlandadvisers.com.au 21
Slide 22: Thank You
THANK YOU 22
Nova Eye Medical — Shareholder Meeting (November 2017) on 6ix